Hijacking the Message: Insights from Targeting mRNA Export and Translation in AML
5 affiliations
- 1Department of Pharmacology, Northwestern University, Chicago, IL 60611, USA
- 2Robert H. Lurie Cancer Center, Northwestern University, Chicago, IL 60611, USA
- 3Division of Hematology/Medical Oncology, Department of Medicine, New York, NY 10021, USA
- 4Sandra & Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY 10021, USA
- 5Pharmacology Department, Weill Cornell Medicine, New York, NY 10021, USA
Abstract
Cancer cells hijack RNA metabolism, including splicing, polyadenylation, nuclear export and translation, to change both the amount and the form of the proteins they produce. This creates therapeutic vulnerabilities beyond the mutations and translocations that have guided drug development in acute myeloid leukemia (AML), where outcomes remain poor. Using AML as a paradigm, this review focuses on two nodes of RNA metabolism: the eukaryotic translation initiation factor eIF4E, a cap-chaperone that escorts mRNAs through processing, export and translation, and CRM1/XPO1, the major nuclear exporter of proteins and select RNAs that partners with eIF4E for specific mRNA export activity. We describe the RNA biology dysregulated in patients, the mechanisms of the inhibitors that target these pathways, and their pre-clinical and clinical data across AML and other malignancies. Indeed, early-stage clinical trials in AML and other malignancies show promise, including the use of CRM1/XPO1 inhibitors (selinexor, eltanexor) and eIF4E inhibitors (including ribavirin and tomivosertib). We discuss how selecting patients by eIF4E status, confirming on-target activity, and designing rational combinations could improve next-generation therapies.
Related
- Flow Cytometry and AI-Driven Biomarker Discovery in Acute Kidney Injury: From Mechanistic Insights to Translation Applications in Clinical and Austere Environments
- A small molecule increases mycobacterial translation fidelity without a fitness cost by targeting ribosomal protein S5
- Emerging Therapeutic Strategies for Targeting Hyaluronan in Metabolic Disease from Molecular Design to Clinical Translation
- Hijacking Cellular S-Acylation with Molecular Assemblies Rewires Oncogenic Signaling
- Ribonucleotide Reductase Dysregulation in Cancer – Oncogenic Hijacking and Novel Therapies: Teaching an Old Dog New Tricks
BibTeX
@article{borden2026hijacking,
title = {{Hijacking the Message: Insights from Targeting mRNA Export and Translation in AML}},
author = {Katherine L. B. Borden and Monica L. Guzman},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = oct,
doi = {10.3390/ijms27209234},
url = {https://www.mdpi.com/1422-0067/27/20/9234},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Hijacking the Message: Insights from Targeting mRNA Export and Translation in AML
AU - Katherine L. B. Borden
AU - Monica L. Guzman
PY - 2026
DA - 2026/10/17
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27209234
UR - https://www.mdpi.com/1422-0067/27/20/9234
AB - Cancer cells hijack RNA metabolism, including splicing, polyadenylation, nuclear export and translation, to change both the amount and the form of the proteins they produce. This creates therapeutic vulnerabilities beyond the mutations and translocations that have guided drug development in acute myeloid leukemia (AML), where outcomes remain poor. Using AML as a paradigm, this review focuses on two nodes of RNA metabolism: the eukaryotic translation initiation factor eIF4E, a cap-chaperone that escorts mRNAs through processing, export and translation, and CRM1/XPO1, the major nuclear exporter of proteins and select RNAs that partners with eIF4E for specific mRNA export activity. We describe the RNA biology dysregulated in patients, the mechanisms of the inhibitors that target these pathways, and their pre-clinical and clinical data across AML and other malignancies. Indeed, early-stage clinical trials in AML and other malignancies show promise, including the use of CRM1/XPO1 inhibitors (selinexor, eltanexor) and eIF4E inhibitors (including ribavirin and tomivosertib). We discuss how selecting patients by eIF4E status, confirming on-target activity, and designing rational combinations could improve next-generation therapies.
SN - 1422-0067
ER -